Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320682 | 0.87 | ALDH1A1 (0.45) | ALDH1A1LMNAHSD17B10CYP2C19KMT2A | |
| SCHEMBL21611822 | 0.82 | ALDH1A1 (0.33) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL21611815 | 0.80 | CYP2C9 (0.34) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL575095 | 0.79 | — | — | |
| SCHEMBL22215092 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL5964972 | 0.78 | ALDH1A1 (0.38) | ALDH1A1LMNAHSD17B10CYP2C19KMT2A | |
| SCHEMBL22228982 | 0.78 | CHRM2 (0.35) | ALDH1A1 | |
| SCHEMBL304788 | 0.78 | ALDH1A1 (0.65) | ALDH1A1LMNAHSD17B10CYP2C19KMT2A | |
| SCHEMBL11986240 | 0.78 | ALDH1A1 (0.38) | ALDH1A1LMNAHSD17B10CYP2C19KMT2A | |
| SCHEMBL9790004 | 0.77 | SOAT1 (0.50) | ALDH1A1LMNAHSD17B10CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| US-9907796-B2 | Methods of treating tumoral diseases, or bacterial or viral infections | INHIBIKASE THERAPEUTICS, INC. (US) | 2018-03-06 | — | — | US | claimed |
| US-20170000789-A1 | Methods of Treating Tumoral Diseases, or Bacterial or Viral Infections | SPHAERA PHARMA PTE. LTD. (SG) | 2017-01-05 | — | — | US | claimed |
| US-9487500-B2 | Compounds and compositions thereof | INHIBIKASE THERAPEUTICS, INC. (US) | 2016-11-08 | — | — | US | claimed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | claimed |
| EP-2903979-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | Inhibikase Therapeutics, Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | PIVOT HOLDING LLC | 2014-05-01 | — | — | US | claimed |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | US | claimed |
| WO-2014055938-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| EP-2693876-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | Sphaera Pharma Pte. Ltd (SG) | 2014-02-12 | — | — | EP | claimed |
| WO-2012137225-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-10-11 | — | — | WO | claimed |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250319113-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ARCUS BIOSCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12168023-B2 | Inhibitors of adenosine 5′-nucleotidase | ARCUS BIOSCIENCES, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240285665-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ARCUS BIOSCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-6043230-A | Use of tenofovir disoproxil fumarate in treatment of HIV | GILEAD SCIENCES, INC. (US) | 2000-03-28 | — | — | US | disclosed |
| US-5977089-A | ORALLY ADMINISTERING TENOFOVIR DERIVATIVES | GILEAD SCIENCES, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5922695-A | COMPOUNDS CONTAINING CARBONATE OR CARBAMATE GROUPS | GILEAD SCIENCES, INC. (US) | 1999-07-13 | — | — | US | disclosed |
| EP-0915894-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998004569-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319113-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ENTPD5, NT5C2, ENTPD1 | ALDH1A1 1329/4885LMNA 2099/4885HSD17B10 4212/4885 |
| US-12168023-B2 | Inhibitors of adenosine 5′-nucleotidase | ENTPD5, NT5C2, ENTPD1 | ALDH1A1 1293/4885LMNA 2120/4885HSD17B10 4200/4885 |
| US-20140121367-A1 | SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS | TPMT, BHMT2, PFAS | ALDH1A1 524/4885LMNA 3888/4885HSD17B10 2396/4885 |
| US-20170000789-A1 | Methods of Treating Tumoral Diseases, or Bacterial or Viral Infections | POLI, RNASE1, VHL | ALDH1A1 1777/4885LMNA 3014/4885HSD17B10 1204/4885 |
| US-12629371-B2 | Compositions and methods for inhibiting kinases | PTK2, HCK, PTK2B | ALDH1A1 1607/4885LMNA 3839/4885HSD17B10 3337/4885 |
| US-20140100225-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | POLI, MCL1, HRAS | ALDH1A1 2478/4885LMNA 2169/4885HSD17B10 3417/4885 |
| US-20240285665-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ENTPD5, NT5C2, ENTPD1 | ALDH1A1 1329/4885LMNA 2099/4885HSD17B10 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.